Drugs Made In America Acquisition
DMAA | NASDAQ
$10.90
$0.00 (0.00%)
At close: Nov 16, 2026, 4:00 PM ET
$10.89
-$0.01 (-0.09%)
After-hours:
Nov 16, 2026, 4:37 PM ET
Drugs Made In America Acquisition Company Profile
Company profile explainedCompany Profile
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Roger Bendelac | Chief Executive Officer |
| Saleem Elmasri | CFO & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2026 | 425 | Filing |
| Oct 21, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 425 | Filing |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 20, 2026 | 425 | Filing |
Drugs Made In America Acquisition
| Country | United States |
| IPO Date | Jan 27, 2025 |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | 2 |
| CEO | Roger Bendelac |
Contact Details
420 Lexington Avenue New York,
New York 10170 United States
Stock Details
| Ticker Symbol | DMAA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002028614 |
| CUSIP Number | G2847J104 |
| ISIN Number | KYG2847J1040 |
| SIC Code | 6770 |
Add to Watchlist
Select watchlists to add or remove DMAA